BMS Acquires Celgene in First Major Deal of 2019
By Michelle Liu & Jawala Prasad
Pharma Deals Review: Vol 2019 Issue 1 (Table of Contents)
Published: 12 Jan-2019
DOI: 10.3833/pdr.v2019.i1.2394 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In the third largest M&A deal of all time, Celgene has agreed to be acquired by Bristol-Myers Squibb (BMS) for approximately US$74 B after a bumpy two years which sent its stock price plummeting over 50% since its peak in September 2017...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS